Drug maker GlaxoSmithKline (GSK) expects to maintain its fast pace of growth in China with additional investments for development of new medicines and vaccines, according to Amy Huang, vice-president and China director.

"GSK does not intend to cut its budget for China this year. We will on the contrary, invest more for developing new medicines," said Huang.

In 2008, GSK achieved a 12 percent growth in sales in emerging markets. China outperformed the others with a 22 percent increase in sales, while the global numbers fell by 3 percent.